Differential dependency of human cancer cells on vascular endothelial growth factor-mediated autocrine growth and survival

Cancer Letters

Volumn 309, Issue 2, 2011, Pages 145-150

  Lee, Jungwhoi ^a   Lee, Jungsul ^a   Yu, Hana ^a   Choi, Kyungsun ^a   Choi, Chulhee ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

Angiogenesis; Autocrine; Brain tumor; Cell signaling; VEGF

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ARTICLE; ASTROCYTOMA; ASTROCYTOMA CELL; AUTOCRINE EFFECT; CANCER CELL; CANCER GROWTH; CELL SURVIVAL; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; FIBROSARCOMA; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL;

ASTROCYTOMA; AUTOCRINE COMMUNICATION; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROSARCOMA; HUMANS; LIVER NEOPLASMS; MICROARRAY ANALYSIS; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT PROTEINS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 79960840344     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.05.026     Document Type: Article

References (26)

1. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841-844.
2. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3:401-410.
3. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 2008, 8:579-591.
4. Gasparini G., Longo R., Toi M., Ferrara N. Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat. Clin. Pract. Oncol. 2005, 2:562-577.
5. Hartenbach E.M., Olson T.A., Goswitz J.J., Mohanraj D., Twiggs L.B., Carson L.F., Ramakrishnan S. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett. 1997, 121:169-175.
6. Nasarre C., Roth M., Jacob L., Roth L., Koncina E., Thien A., Labourdette G., Poulet P., Hubert P., Cremel G., Roussel G., Aunis D., Bagnard D. Peptide-based interference of the transmembrane domain of neuropilin-1 inhibits glioma growth in vivo. Oncogene 2010, 29:2381-2392.
7. Takahashi H., Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin. Sci. (Lond.) 2005, 109:227-241.
8. Ferrara N., Hillan K.J., Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophys. Res. Commun. 2005, 333:328-335.
9. Shibuya M., Yamaguchi S., Yamane A., Ikeda T., Tojo A., Matsushime H., Sato M. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990, 5:519-524.
10. Matthews W., Jordan C.T., Gavin M., Jenkins N.A., Copeland N.G., Lemischka I.R. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc. Natl. Acad. Sci. USA 1991, 88:9026-9030.
11. Olsson A.K., Dimberg A., Kreuger J., Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell Biol. 2006, 7:359-371.
12. Waltenberger J., Claesson-Welsh L., Siegbahn A., Shibuya M., Heldin C.H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem. 1994, 269:26988-26995.
13. Gao C., F H.T., Nowinski W. A finite element method based deformable brain atlas suited for surgery simulation. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2005, 4:4337-4340.
14. Gille H., Kowalski J., Li B., LeCouter J., Moffat B., Zioncheck T.F., Pelletier N., Ferrara N. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J. Biol. Chem. 2001, 276:3222-3230.
15. Hong T.M., Chen Y.L., Wu Y.Y., Yuan A., Chao Y.C., Chung Y.C., Wu M.H., Yang S.C., Pan S.H., Shih J.Y., Chan W.K., Yang P.C. Targeting neuropilin 1 as an antitumor strategy in lung cancer. Clin. Cancer Res. 2007, 13:4759-4768.
16. Wang E.S., Teruya-Feldstein J., Wu Y., Zhu Z., Hicklin D.J., Moore M.A. Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood 2004, 104:2893-2902.
17. Spannuth W.A., Nick A.M., Jennings N.B., Armaiz-Pena G.N., Mangala L.S., Danes C.G., Lin Y.G., Merritt W.M., Thaker P.H., Kamat A.A., Han L.Y., Tonra J.R., Coleman R.L., Ellis L.M., Sood A.K. Functional significance of VEGFR-2 on ovarian cancer cells. Int. J. Cancer 2009, 124:1045-1053.
18. Song S., Kang S.W., Choi C. Trichostatin A enhances proliferation and migration of vascular smooth muscle cells by downregulating thioredoxin 1. Cardiovasc. Res. 2010, 85:241-249.
19. Jeon J., Lee J., Kim C., An Y., Choi C. Aqueous extract of the medicinal plant Patrinia villosa Juss. Induces angiogenesis via activation of focal adhesion kinase. Microvasc. Res. 2010, 80:303-309.
20. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., Scheithauer B.W., Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114:97-109.
21. Berra E., Pages G., Pouyssegur J. MAP kinases and hypoxia in the control of VEGF expression. Cancer Metastasis Rev. 2000, 19:139-145.
22. Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
23. Karl E., Zhang Z., Dong Z., Neiva K.G., Soengas M.S., Koch A.E., Polverini P.J., Nunez G., Nor J.E. Unidirectional crosstalk between Bcl-xL and Bcl-2 enhances the angiogenic phenotype of endothelial cells. Cell Death Differ. 2007, 14:1657-1666.
24. Du R., Lu K.V., Petritsch C., Liu P., Ganss R., Passegue E., Song H., Vandenberg S., Johnson R.S., Werb Z., Bergers G. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008, 13:206-220.
25. Aesoy R., Sanchez B.C., Norum J.H., Lewensohn R., Viktorsson K., Linderholm B. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells. Mol. Cancer Res. 2008, 6:1630-1638.
26. Kreisl T.N., Kim L., Moore K., Duic P., Royce C., Stroud I., Garren N., Mackey M., Butman J.A., Camphausen K., Park J., Albert P.S., Fine H.A. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 2009, 27:740-745.